IP Library Granted Patent US 9,579,406
Granted Patent B2
US 9,579,406 · App. 14/501,473 · Granted Feb 28, 2017

Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof

Inventors: Jamey P. Weichert (Fitchburg, WI); Marc Longino (Verona, WI); Anatoly Pinchuk (Madison, WI)
Assignee: CELLECTAR BIOSCIENCES, INC.
A61K51/0408A61K49/0017A61K51/04C07F13/005G01N33/57492
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,579,406
App. No.
14/501,473
Granted
Feb 28, 2017
Kind
B2
Abstract

The present invention provides methods for treating, detecting and locating recurrence of cancer, radiation and chemo insensitive cancer or metastasis of cancer selected from the group consisting of Lung cancer, Adrenal cancer, Melanoma, Colon cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Liver cancer, Subcutaneous cancer, Squamous cell cancer, Intestinal cancer, Hepatocellular carcinoma, Retinoblastoma, Cervical cancer, Glioma, Breast cancer and Pancreatic cancer in subject using phospholipid ether analogs.

Claims (6)

1. A method for detecting radiation- and chemo-insensitive cancer or cancer metastasis in a subject, comprising:

administering 124 I-labeled 18-(p-iodophenyl)octadecylphosphocholine to the subject; and

determining whether an organ of the subject suspected of having radiation- and chemo-insensitive cancer or cancer metastasis retains a higher level of 124 I-labeled 18-(p-iodophenyl)octadecylphosphocholine than surrounding regions wherein a higher retention region indicates detection of radiation- and chemo-insensitive cancer or cancer metastasis by measuring 124 I radioactivity in the subject.

2. The method of claim 1 wherein 124 I radioactivity is measured using PET scanning and wherein the organ of the subject suspected of having radiation- and chemo-insensitive cancer or cancer metastasis is detected by MRI.

3. The method of claim 1 wherein 124 I radioactivity is measured using SPECT.

4. The method of claim 1 wherein 124 I radioactivity is measured using gamma camera scintigraphy.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2014
From: WEICHERT, JAMEY; LONGINO, MARC; PINCHUK, ANATOLY
To: CELLECTAR, LLC
Reel/Frame 033899/0086 →
MERGER Recorded Oct 7, 2014
From: CELLECTAR, INC.
To: CELL ACQUISITION CORP.
Reel/Frame 033899/0117 →
CONVERSION Recorded Oct 7, 2014
From: CELLECTAR, LLC
To: CELLECTAR, INC.
Reel/Frame 033899/0175 →
CHANGE OF NAME Recorded Oct 7, 2014
From: CELL ACQUISITION CORP.
To: CELLECTAR, INC.
Reel/Frame 033899/0280 →
Continuity (6)
Continuation 13964380 · Aug 12, 2013
Continuation 11316620 · Dec 20, 2005
Continuation In Part 10906687 · Mar 2, 2005
Provisional Application 60521166 · Mar 2, 2004
Provisional Application 60593190 · Dec 20, 2004
Related Publication 20150030538A1 · Jan 29, 2015